Refine by
In Vivo Efficacy Suppliers & Manufacturers
9 companies found
based inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by ...
based inAmes, ALABAMA (USA)
Mazen Animal Health harnesses the power of plant biotechnology to create orally delivered biologics, aimed at significantly improving animal health and welfare. The company's innovative cross-species platform is versatile enough to target various ...
This pioneering approach enhances animal welfare, worker safety, and biosecurity by leveraging mucosal immunity to protect against pathogens. The platform's efficacy is driven by a methodical process including protein design, where ...
based inNorthwood, OHIO (USA)
NAMSA is medical research organization providing expert regulatory, laboratory, clinical, and compliance services to medical device and healthcare product manufacturers. At every stage of the product development process, we provide strategic ...
If your device doesn’t perform according to its intended function, your agenda can be turned upside down. So when you’re looking for an accelerated path to market, you want a partner who offers a broad range of in vivo models and ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
Pharmaceutical chemical and biology researchers need to develop new methods and models to improve the predictivity of preclinical discovery phases and increase the number of good molecules in clinic. INOVOTION’s unique in vivo technology ...
based inCarmel, INDIANA (USA)
Sword Diagnostics is a cutting-edge life sciences company created in response to the rapidly evolving needs of the research and pharmaceutical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and ...
Utilizing our proprietary Sword Swift™ Method Development Process and Sword Swift™ Detection Reagents, our scientists can develop sensitive quantitative assays to measure the amounts of free or bound drug in preclinical or clinical ...
based inWhite Plains, NEW YORK (USA)
Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy ...
based inTralee, IRELAND
BioAtlantis was established in 2004 and entered the crop biostimulant market in 2007 with stress mitigation as a central strategy. Stress is now recognised worldwide as affecting most life forms. It can be split into two main categories, abiotic and ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2].Riviciclib hydrochloride (P276-00) shows ...
based inMölndal, SWEDEN
Alzinova AB is a Swedish clinical-stage biopharma company pioneering the development of an active immunotherapy against Alzheimer’s disease. The vaccine is in clinical development and tested in patients. The company’s shares (ALZ) are listed on ...
ALZ-101 is a vaccine that stimulates the production of antibodies against the toxic Aβ oligomers. A first-in-human study in patients with early Alzheimer’s disease was initiated during third quarter of ...